DE69827805D1 - Verfahren und vorrichtung zur bestimmung des transformationspotentials von verbindungen. - Google Patents

Verfahren und vorrichtung zur bestimmung des transformationspotentials von verbindungen.

Info

Publication number
DE69827805D1
DE69827805D1 DE69827805T DE69827805T DE69827805D1 DE 69827805 D1 DE69827805 D1 DE 69827805D1 DE 69827805 T DE69827805 T DE 69827805T DE 69827805 T DE69827805 T DE 69827805T DE 69827805 D1 DE69827805 D1 DE 69827805D1
Authority
DE
Germany
Prior art keywords
apoptin
cells
cancer
normal
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69827805T
Other languages
English (en)
Other versions
DE69827805T2 (de
Inventor
Hubertus Noteborn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leadd BV
Original Assignee
Leadd BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadd BV filed Critical Leadd BV
Publication of DE69827805D1 publication Critical patent/DE69827805D1/de
Application granted granted Critical
Publication of DE69827805T2 publication Critical patent/DE69827805T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
DE69827805T 1997-08-12 1998-08-11 Verfahren und vorrichtung zur bestimmung des transformationspotentials von verbindungen. Expired - Lifetime DE69827805T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97202501 1997-08-12
EP97202501 1997-08-12
PCT/NL1998/000457 WO1999008108A1 (en) 1997-08-12 1998-08-11 Determining the transforming capability of agents

Publications (2)

Publication Number Publication Date
DE69827805D1 true DE69827805D1 (de) 2004-12-30
DE69827805T2 DE69827805T2 (de) 2005-12-15

Family

ID=8228640

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69827805T Expired - Lifetime DE69827805T2 (de) 1997-08-12 1998-08-11 Verfahren und vorrichtung zur bestimmung des transformationspotentials von verbindungen.

Country Status (16)

Country Link
US (1) US6528247B1 (de)
EP (1) EP1004021B1 (de)
JP (1) JP4287588B2 (de)
KR (1) KR20010022812A (de)
AT (1) ATE283478T1 (de)
AU (1) AU756587B2 (de)
BR (1) BR9811163A (de)
CA (1) CA2301401C (de)
CZ (1) CZ299874B6 (de)
DE (1) DE69827805T2 (de)
NO (1) NO326659B1 (de)
NZ (1) NZ502800A (de)
PL (1) PL196605B1 (de)
RU (1) RU2214598C2 (de)
SK (1) SK286235B6 (de)
WO (1) WO1999008108A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW514581B (en) * 1999-09-02 2002-12-21 Ciba Sc Holding Ag A method of protecting wood against light-induced degradation by treatment with an impregnation which penetrates the surface of the wood
EP1083224B1 (de) 1999-09-02 2006-12-06 Leadd B.V. Apoptin bindendes Protein
IL150134A0 (en) 1999-12-10 2002-12-01 Leadd Bv Apoptin-associating protein
EP1199363A1 (de) 2000-10-20 2002-04-24 Leadd B.V. Phosphorylationsmodifikationen von Apoptin
DE60229924D1 (de) * 2001-03-30 2009-01-02 Leadd Bv Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
SE0302312D0 (sv) * 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
AU2003904086A0 (en) 2003-08-04 2003-08-21 Cochlear Limited Implant battery short circuit protection
WO2012091563A1 (en) 2010-12-27 2012-07-05 Apo-T B.V. A polypeptide that binds aberrant cells and induces apoptosis
JP2014530009A (ja) 2011-09-29 2014-11-17 エーピーオー‐ティー ビー．ヴイ． 異常細胞を標的とする多重特異性結合分子
CA2860914A1 (en) 2012-01-13 2013-07-18 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9002008A (nl) 1990-09-12 1992-04-01 Stichting Centr Diergeneeskund Recombinant dna en rna en daarvan afgeleide produkten.
EP0816851A3 (de) * 1991-01-15 2000-08-23 Oy Biotie Therapies Nachweis des Syndecangehalts in Körperflüssigkeiten zur Anzeige der bösartigen Umwandlung von Zellen
EP0878546A1 (de) 1997-04-15 1998-11-18 Leadd B.V. Genabgabe-Vehikel die das Apoptosis VP2 inducierendes Protein, und/oder Apoptin exprimiert
CZ82692A3 (en) * 1992-03-19 1994-02-16 Prirodovedecka Fakulta Uk Method of testing cyctotoxicity and genotoxicity of chemicals
ATE241808T1 (de) 1995-06-07 2003-06-15 Leadd Bv Verwendungen von apoptin
JPH1015250A (ja) 1996-06-28 1998-01-20 Sega Enterp Ltd ゲーム装置
EP0927757A1 (de) * 1997-12-03 1999-07-07 Leadd B.V. Verfahren und Mitteln um Apoptose zu induzieren durch Interferenz mit Bip-ähnliche Proteine
EP0921192A1 (de) * 1997-12-03 1999-06-09 Leadd B.V. Molekulen interagierend mit Apoptin

Also Published As

Publication number Publication date
BR9811163A (pt) 2000-07-25
JP2001512829A (ja) 2001-08-28
ATE283478T1 (de) 2004-12-15
CA2301401A1 (en) 1999-02-18
NZ502800A (en) 2002-10-25
US6528247B1 (en) 2003-03-04
CZ299874B6 (cs) 2008-12-17
AU8752998A (en) 1999-03-01
RU2214598C2 (ru) 2003-10-20
EP1004021B1 (de) 2004-11-24
PL196605B1 (pl) 2008-01-31
NO20000736L (no) 2000-04-11
WO1999008108A1 (en) 1999-02-18
DE69827805T2 (de) 2005-12-15
KR20010022812A (ko) 2001-03-26
AU756587B2 (en) 2003-01-16
JP4287588B2 (ja) 2009-07-01
NO326659B1 (no) 2009-01-26
NO20000736D0 (no) 2000-02-14
EP1004021A1 (de) 2000-05-31
CA2301401C (en) 2008-10-21
SK1902000A3 (en) 2000-11-07
PL338683A1 (en) 2000-11-20
SK286235B6 (sk) 2008-06-06
CZ2000479A3 (cs) 2000-06-14

Similar Documents

Publication Publication Date Title
ATE223727T1 (de) Erkennung und modulierung von iaps und naip zur diagnose und behandlung von proliferativen erkrankungen
DE60126592D1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
ATE287210T1 (de) Behandlung von lösungen roter blutkörperchen mit antiviralen wirkstoffen
DE69827805D1 (de) Verfahren und vorrichtung zur bestimmung des transformationspotentials von verbindungen.
DE69528653T2 (de) Genetische diagnose und pharmazeutische produkte zur behandlung von prostatakrebs
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
DE69633717D1 (de) Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
NO920125D0 (no) Fremgangsmaate for aa bestemme den funksjonelle aktivitetentil fri protein s eller protein c i en plasma-proeve
DE59912716D1 (de) Verfahren zur bestimmung der immunabwehraktivität des blutes sowie testkit hierfür
DE69705936D1 (de) Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose
DE69329656D1 (de) Methoden zur detektion und behandlung von individuen mit abnormalen hla-a2/tyrosinase-peptidantigenen exprimierenden zellen
DE69628431D1 (de) Verwendungen von apoptin
ATE214101T1 (de) Expression von heterologen genen in menschlichen brustzellen, einschliesslich menschliche brustkarzionomzellen unter der kontrolle von regulatorischen sequenzen von wap oder mmtv
ATE323176T1 (de) Nachweis von brusttumorvirus-artigen sequenzen in brustkrebs bei menschen
DE69016858D1 (de) Verfahren und Reagenziensatz zur Bestimmung der funktionalen Aktivität von Protein S in menschlichem Plasma.
DE60113968D1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
HUP0101285A2 (hu) Eljárások és készítmények a hepatóma diagnosztizálására
ATE435284T1 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
Beckman et al. The human placental amino acid naphthylamidases; their molecular interrelations and correlations with perinatal factors
FI971879A0 (fi) Allogeenisten ja ksenogeenisten proteiinien vasta-aineet, niiden käyttö diagnoosissa ja hoidossa ja menetelmät niiden määrittämiseksi
DE60007864D1 (de) Verwendung von antileukoprotease zur behandlung von endometriose
ATE8712T1 (de) Diagnostizierverfahren, insbesondere zur frueherkennung von malignen tumoren und/oder viralen erkrankungen und mittel zu seiner durchfuehrung.
ATE5254T1 (de) Tripeptidderivate und verfahren zur bestimmung von enzymen mittels derselben.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition